Status:
RECRUITING
Evaluation of Monocyte Expression of HLA-DR (mHLA-DR) in Geriatric Service
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Immune System
Eligibility:
All Genders
75+ years
Brief Summary
The acceleration of population aging and the improved management of comorbidities lead to an increase in the number of multi-pathological elderly patients admitted to geriatric services. This is an ex...
Eligibility Criteria
Inclusion
- For all patients:
- Patients aged over 75 hospitalised in one of the geriatric units defined as the research sites;
- Patient affiliated to a social security scheme;
- Patients or relatives who have been informed and have no objections to the research.
- To be eligible in the acute situation sub-population:
- \- Patients presenting with an acute episode on admission or following a stay in the research sites; The acute episode is defined, for example, by an infection, cardiac decompensation, a complicated fall, acute renal failure, any acute or decompensated cardiovascular pathology, any discovery of cancer that has not been stabilised.
- To be eligible in the stable situation sub-population:
- \- A patient who has not had an acute episode for at least 7 days.
Exclusion
- For all patients:
- Patients under legal protection: curatorship, guardianship, safeguard of justice ;
- Patients under exclusive comfort care for whom it has been decided not to take a blood sample;
- Patients undergoing long-term antibiotic treatment, i.e. with no defined stopping date;
- An immunocompromised patient or a patient undergoing immunosuppressive treatment (for example: HIV infection, a patient awaiting solid organ transplantation, a patient undergoing haematopoietic stem cell transplantation, a patient undergoing chemotherapy for a solid tumour or haematological malignancy, a patient suffering from an auto-immune disease and being treated with immunotherapy and/or immunosuppressive therapy and/or biotherapy, an asplenic or hyposplenic patient, a patient undergoing experimental potentially immunosuppressive treatment, a patient undergoing Eculizumab treatment, a patient presenting a hereditary immune deficiency).
- For patients in an acute clinical situation:
- \- Patient previously included in the same sub-population.
Key Trial Info
Start Date :
January 6 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06513520
Start Date
January 6 2025
End Date
January 31 2026
Last Update
January 30 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dugoujon Hospital
Caluire-et-Cuire, France, 69300
2
Croix Rousse hospital
Lyon, France, 69004